Tevogen Bio Holdings Inc. has announced an update on the development of its EBV-specific T cell therapy, which targets Epstein-Barr virus-associated lymphomas. The company is in the process of selecting EBV peptides using computer-based methods as part of its preparation for a potential clinical trial. This trial will utilize EBV-specific CTLs manufactured with Tevogen's proprietary ExacTcell™ technology, known for its precision and scalability. The company's R&D laboratory has also commenced confirmation studies to validate CTL responses to the selected viral peptides. Tevogen Bio's scientific and clinical teams are collaborating with Tevogen.AI to advance peptide selection strategies, aiming to enhance therapeutic precision. The research is currently in the preclinical evaluation phase, and further updates will be provided as the study progresses. Results from this research have not yet been presented.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.